Baseline characteristics of the enrolled patients (IMAGE)
Caption
The baseline characteristics of the 46 patients enrolled in this study included a median age of 55 years (IQR: 46–59), with 85% aged 40 or older. Among the patients, 59% had HER2 3+ status, and 41% had HER2 2+ confirmed through FISH testing. Estrogen receptor (ER) expression was ≥50% in 70% of patients, while 78% had progesterone receptor (PR) expression <50%. Additionally, 59% of patients received the combination therapy as first-line treatment, while 41% were treated as second-line. Approximately 54% exhibited secondary resistance to trastuzumab, highlighting the complexity of this patient cohort.本研究纳入的46例患者的基线特征包括中位年龄为55岁(IQR: 46 - 59), 85%的患者年龄在40岁或以上。在患者中,59%的人有HER2 - 3状态,41%的人通过FISH检测证实HER2。70%的患者雌激素受体(ER)表达≥50%,78%的患者孕激素受体(PR)表达<50%。此外,59%的患者接受联合治疗作为一线治疗,41%的患者接受二线治疗。大约54%的患者表现出对曲妥珠单抗的继发性耐药,这突出了该患者队列的复杂性。
Credit
Ying Wang
Usage Restrictions
Please cite source
License
Original content